1059189-63-7

Usage

Uses

Used in Pharmaceutical Research:
(2R,3R)-N-tert-butoxycarbonyl-3-amino-4-(4-benzyloxyphenyl)-1-chloro-2-hydroxybutane is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and functional groups make it a valuable building block for the creation of novel drug candidates.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, (2R,3R)-N-tert-butoxycarbonyl-3-amino-4-(4-benzyloxyphenyl)-1-chloro-2-hydroxybutane is used as a structural component in the design and development of new therapeutic agents. Its versatility and the presence of the Boc protecting group allow for selective protection and modification of the amino group, which can be crucial for optimizing the pharmacological properties of the resulting compounds.
Used in Organic Synthesis:
(2R,3R)-N-tert-butoxycarbonyl-3-amino-4-(4-benzyloxyphenyl)-1-chloro-2-hydroxybutane is also employed as a versatile reagent in organic synthesis, where its functional groups can be utilized for a wide range of chemical reactions. This allows for the creation of diverse chemical products and further expands the compound's applications across various industries.

Upstream product

• 152438-62-5 (S)-N-[3-Chloro-2-oxo-1-[[4-(phenylmethoxy)phenyl]methyl]propyl]carbamic acid 1,1-dimethylethyl ester 
• 1026977-99-0 C₂₆H₃₃NO₇ 
• 114645-18-0 [1-(4-benzyloxy-benzyl)-3-diazo-2-oxo-propyl]-carbamic acid tert-butyl ester 
• 2130-96-3 O-benzyl-N-tert-butoxycarbonyl-L-tyrosine 
• 127132-32-5 ethyl N-{[(1,1-dimethylethyl)oxy]carbonyl}-O-(phenylmethyl)-L-tyrosinate 

Relevant academic research and scientific papers

Novel P1 chain-extended HIV protease inhibitors possessing potent anti-HIV activity and remarkable inverse antiviral resistance profiles

A novel series of tyrosine-derived HIV protease inhibitors was synthesized and evaluated for in vitro antiviral activity against wild-type virus and two protease inhibitor-resistant viruses. All of the compounds had wild-type antiviral activities that were similar to or greater than several currently marketed HIV protease inhibitors. In addition, a number of compounds in this series were more potent against the drug-resistant mutant viruses than they were against wild-type virus.

PROCESS FOR PRODUCING AMINOEPOXIDE

The present invention relates to a method of producing N-carbamate protected-3-amino-1,2-epoxy-4-(hydroxy substituted phenyl)butane at a high optical purity in a high yield, by hydrogenating N-carbamate protected-3-amino-1-chloro-2-hydroxy-4-(benzyloxy su

Aminodiol HIV protease inhibitors. Synthesis and structure - Activity relationships of P1/P1′ compounds: Correlation between lipophilicity and cytotoxicity

A series of novel aminodiol inhibitors of HIV protease based on the lead compound 1 with structural modifications at P1′ were synthesized in order to reduce the cytotoxicity of 1. We have observed a high degree of correlation between the lipophilicity and the cytotoxicity of this series of inhibitors. It was found that appropriate substitution at the para position of the P1′ phenyl group of 1 resulted in the identification of equipotent (both against the enzyme and in cell culture) compounds (101, 10m, 10n, and 15c) which possess significantly decreased cytotoxicity.